Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE
Autore:
BIALER M; JOHANNESSEN SI; KUPFERBERG HJ; LEVY RH; LOISEAU P; PERUCCA E;
Indirizzi:
HEBREW UNIV JERUSALEM,FAC MED,SCH PHARM IL-91120 JERUSALEM ISRAEL NATL CTR EPILEPSY SANDVIKA NORWAY NINCDS,EPILEPSY BRANCH,NIH BETHESDA MD 20892 UNIV WASHINGTON,DEPT PHARMACEUT SEATTLE WA 98195 UNIV WASHINGTON,DEPT NEUROL SURG SEATTLE WA 98195 UNIV BORDEAUX 1,HOSP PELLEGRIN,DEPT NEUROL BORDEAUX FRANCE UNIV PAVIA,DEPT INTERNAL MED & THERAPEUT,CLIN PHARMACOL UNIT I-27100 PAVIA ITALY
Titolo Testata:
Epilepsy research
fascicolo: 3, volume: 25, anno: 1996,
pagine: 299 - 319
SICI:
0920-1211(1996)25:3<299:PRONAD>2.0.ZU;2-5
Fonte:
ISI
Lingua:
ENG
Soggetto:
NEWLY-DIAGNOSED EPILEPSY; CARBAMAZEPINE; CLOBAZAM; PROFILE;
Keywords:
ANTIEPILEPTIC DRUG DEVELOPMENT; CLINICAL TRIAL DESIGN; DRUG APPROVAL;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
40
Recensione:
Indirizzi per estratti:
Citazione:
M. Bialer et al., "PROGRESS REPORT ON NEW ANTIEPILEPTIC DRUGS - A SUMMARY OF THE 3RD EILAT CONFERENCE", Epilepsy research, 25(3), 1996, pp. 299-319

Abstract

The Third Eilat Conference on New Antiepileptic Drugs was held at theRoyal Beach Hotel from May 27 to May 30, 1996. Epileptologists and scientists from 20 countries attended the conference, which was held to discuss critical issues in drug development, new antiepileptic drugs (AEDs) in development, progress reports and recent findings of newly marketed AEDs, the use of AEDs in special populations and their utilization in non-epileptic disorders. Over the last seven years, six new AEDs have been introduced worldwide and new information on their safety and efficacy has become available. These include felbamate, gabapentin,lamotrigine, oxcarbazepine, topiramate and vigabatrin. Drugs in development include those at an advanced stage, such as remacemide and tiagabine, as well as those just entering clinical trials, such as rufinamide (CGP 331010) and levetiracetam (ucb LO59). The following is a summary of the presentations for drugs in development and recent findings on newly marketed drugs.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 30/11/20 alle ore 20:05:14